The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules

This is an analysis from a chemical point of view of the 46 drugs (34 New Chemical Entities and 12 Biologics) approved by the FDA during 2017. The drugs included in the 2017 "harvest" have been classified on the basis of their chemical structure: biologics (antibodies and proteins); peptid...

Full description

Saved in:
Bibliographic Details
Published inMolecules (Basel, Switzerland) Vol. 23; no. 3; p. 533
Main Authors de la Torre, Beatriz G, Albericio, Fernando
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 27.02.2018
MDPI
Subjects
Amino acids
Antibodies
API
Arthritis
Asthma
Biological products
biologics
Blood pressure
chemical entities
Chemotherapy
Constipation
Diabetes
drug discovery
Drugs
Enzymes
FDA approval
Glucagon
Hemophilia
Leukemia
Multiple sclerosis
Natural products
Organic chemistry
Peer review
peptide
Peptides
Pharmaceutical industry
Proteins
Psoriasis
Review
Sepsis
small molecules
peptide
API
biologics
drug discovery
small molecules
chemical entities
Online AccessGet full text

Cover

More Information
Summary:This is an analysis from a chemical point of view of the 46 drugs (34 New Chemical Entities and 12 Biologics) approved by the FDA during 2017. The drugs included in the 2017 "harvest" have been classified on the basis of their chemical structure: biologics (antibodies and proteins); peptides; amino acids and natural products; drug combinations; and small molecules.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1420-3049
1420-3049
DOI:10.3390/molecules23030533